Journal of Periodontal and Implant Science

  • 제39권1호
  • /
  • Pages.1-8
  • /
  • 2009
  • /
  • 2093-2278(pISSN)
  • /
  • 2093-2286(eISSN)
대한치주과학회 (Korean Academy of Periodontology)
권호 표지

Bisphosphonates induced osteonecrosis of the jaw의 기전, 예방, 위험 평가 및 치료 방법

Mechanism, prevention, risk assessment and treatment in bisphosphonates induced osteonecrosis of the jaw

  • 박정철 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 정의원 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 김창성 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 조규성 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 채중규 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 김종관 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소) ;
  • 최성호 (연세대학교 치과대학 치주과학교실, 치주조직재생연구소)
  • Park, Jung-Chul (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) ;
  • Jung, Ui-Won (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) ;
  • Kim, Chang-Sung (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) ;
  • Cho, Kyoo-Sung (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) ;
  • Chai, Jung-Kiu (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) ;
  • Kim, Chong-Kwan (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) ;
  • Choi, Seong-Ho (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University)
  • 발행 : 2009.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Bisphosphonates are drugs used to suppress osteoclastic activity and to treat osteoporosis, Paget's disease of bone and bone metastasis. The purpose of this report is to review the literatures on bisphosphonates use that could affect bone healing and cause osteonecrosis of the jaws. Materials and methods: Medline research was carried out to find relevant articles on bisphosphonates and osteonecrosis of the jaw. Results: Oral administration of bisphosphonates is reported to decrease the risk of adverse bone outcomes. On the contrary, IV bisphosphonates is known to significantly increase the risk. Prevention of the osteonecrosis of the jaw is primary concern before usage. If the adverse bone reaction takes place, proper management and treatments are required to alleviate pain of patients and prevent further progression of necrosis. Conclusion: Case reports of bisphosphonates induced osteonecrosis of the jaw are increasing. Dentists and physicians should be aware of the higher frequency of osteonecrosis of the jaw in patients receiving IV bisphosphonates and be prepared to prevent and cope with adverse bone reaction.

키워드

참고문헌

  1. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006; 28:151-173 https://doi.org/10.1016/j.clinthera.2006.02.007
  2. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952 https://doi.org/10.1200/JCO.2005.04.2465
  3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S1. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534 https://doi.org/10.1016/j.joms.2004.02.004
  4. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736 https://doi.org/10.1200/JCO.2002.06.037
  5. Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11:S290-308; quiz S309-312
  6. Brooks JK, Gilson AJ, Sindler AJ, et al. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103 :780-786 https://doi.org/10.1016/j.tripleo.2006.10.010
  7. Wynn RL. Oral bisphosphonates and osteonecrosis of the jaw. Gen Dent 2007;55:8-10
  8. Marx RE. Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117 https://doi.org/10.1016/S0278-2391(03)00720-1
  9. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21 :4253-4254 https://doi.org/10.1200/JCO.2003.99.141
  10. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491
  11. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587 https://doi.org/10.1200/JCO.2005.02.8670
  12. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40 https://doi.org/10.14219/jada.archive.2008.0017
  13. Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-2281 https://doi.org/10.1056/NEJMp068157
  14. Boonyapakom T, Schirmer I, Reichart PA, et al. Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-869 https://doi.org/10.1016/j.oraloncology.2007.11.012
  15. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423 https://doi.org/10.1016/j.joms.2006.10.061
  16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zole-dronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822 https://doi.org/10.1056/NEJMoa067312
  17. Etminan M, Aminzadeh K, Matthew JR, Brophy JM. Use of oral bi;:.phosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 2008;35 :691-695
  18. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 2008; 139:23-30 https://doi.org/10.14219/jada.archive.2008.0016
  19. Edwards BJ, Hellstein JW, Jacobsen PL, et aL Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-1677 https://doi.org/10.14219/jada.archive.2008.0110
  20. Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009; 140:61-66 https://doi.org/10.14219/jada.archive.2009.0019
  21. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphateon hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-903 https://doi.org/10.1038/212901a0
  22. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4 https://doi.org/10.1186/bcr487
  23. Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9 Suppl 4:3-13
  24. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376 https://doi.org/10.1016/j.joms.2006.11.003
  25. Rogers MJ, Gordon S, Benford HL, et aL Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978 https://doi.org/10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
  26. Benford HL, Frith JC, Auriola S, et aL Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56: 131-140 https://doi.org/10.1124/mol.56.1.131
  27. Bergstrom JD, Bostedor RG, Masarachia PJ, et a!. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373: 231-241 https://doi.org/10.1006/abbi.1999.1502
  28. Lehenkari PP, Kellinsalmi M, Napankangas JP, et a!. Further insight into mechanism of action of clodronate: 111- hibition of mitochondrial ADP/ATP translocasc by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61 :1255-1262 https://doi.org/10.1124/mol.61.5.1255
  29. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003;32:253-271 https://doi.org/10.1016/S0889-8529(02)00079-8
  30. Alakangas A, Selander K, Mulari M, et a!. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002;70:40-47 https://doi.org/10.1007/s002230010047
  31. Dixon R, Tricker N, Garetto L. Bone turnover in elderly canine mandibles and tibia. J Dent Res 76(IADR Abstracts) 1997:2579
  32. Vignery A, Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 1980; 196: 191-200
  33. Brunski JB. In vivo bone response to biomechanical loading at the bone/dental-implant interface. Adv Dent Res 1999; 13:99-119 https://doi.org/10.1177/08959374990130012301
  34. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544
  35. Reid lR, Bolland M J, Grey AB. Is bisphosphonatcassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41 :318-320 https://doi.org/10.1016/j.bone.2007.04.196
  36. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 2007;19:487-498, v-vi https://doi.org/10.1016/j.coms.2007.07.003
  37. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35: 155-160 https://doi.org/10.1111/j.1600-0714.2006.00391.x
  38. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15: 197-202 https://doi.org/10.1007/s00520-006-0120-z
  39. Ficarra G, Beninati F, Rubino I, et a!. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32: 1123-8 https://doi.org/10.1111/j.1600-051X.2005.00842.x
  40. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575 https://doi.org/10.1016/j.joms.2005.07.010
  41. Bagan lV, Jimenez Y, Murillo J, et aL Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oneol 2006;42:327-329 https://doi.org/10.1016/j.oraloncology.2005.08.001
  42. Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410 https://doi.org/10.1016/j.joms.2007.08.003
  43. Friberg B, Ekestubbe A, Mellstrom D, Sennerby L. Branemark implants and osteoporosis: a clinical exploratory study. Clin Implant Dent Relat Res 2001;3:50-56 https://doi.org/10.1111/j.1708-8208.2001.tb00128.x
  44. Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3 https://doi.org/10.1007/PL00005830
  45. Schwartz IE. Ask us: Some drugs affect tooth movement. Am J Orthod Dentofacial Orthop 2005;127:644 https://doi.org/10.1016/j.ajodo.2005.04.028
  46. Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 2007; 131 :321-326 https://doi.org/10.1016/j.ajodo.2006.11.002
  47. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21 :349-353
  48. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:584-594 https://doi.org/10.1902/jop.2007.060239
  49. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761 https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  50. IMS, HEALTH. NPA Plus May, 2006.